Skip to main content
SpringerLink
Log in

Quantifizierung der Somatostatinrezeptorexpression neuroendokriner Tumoren mit der 68Ga-DOTATATE-PET/CT

Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT

  • Leitthema
  • Published:
Der Radiologe Aims and scope Submit manuscript

Zusammenfassung

Ziel

Vergleich der immunhistochemischen Expression des Somatostatinrezeptor- (SSTR-)Subtyps 2 mit der quantitativen 68Ga-DOTATATE-PET bei neuroendokrinen Tumoren (NET).

Patienten und Methoden

Bei 27 Patienten mit metastasierten NET wurde die immunhistochemische Expression des SSTR-Typs 2 anhand einer Graduierung (0–3) bestimmt. Zusätzlich konnte bei 25/27 Patienten der Proliferationsindex Ki-67 ermittelt werden. Damit verglichen wurde die Speicherung von 68Ga-DOTATATE anhand des SUVmax (SUV „standardized uptake value“).

Ergebnisse

NET ohne SSTR-Expression wiesen einen signifikant (p <0,05) niedrigeren SUVmax auf als Tumoren mit nachgewiesener Expression von SSTR. Es zeigte sich eine signifikante Korrelation zwischen der SSTR-Expression (Grad 0 fehlend, Grad 1 mäßig, Grade 2 und 3 deutlich) und dem SUVmax (r=0,40, p <0,05). Der Ki-67 korrelierte signifikant invers mit der SSTR-Expression (r=−0,42, p <0,05) und nicht signifikant invers mit dem SUVmax (r=−0,33, p=0,11).

Schlussfolgerung

Die 68Ga-DOTATATE-Speicherung in der PET korreliert mit der immunhistochemischen SSTR-Expression. Jedoch können auch immunhistochemisch SSTR-negative NET in der 68Ga-DOTATATE-PET eine Speicherung aufweisen.

Abstract

Purpose

The immunohistochemical expression of somatostatin receptor (SSTR) subtype 2 was compared to quantitative 68Ga-DOTATATE PET in neuroendocrine tumors (NET).

Material and methods

In 27 patients suffering from metastatic NET the expression of somatostatin receptors (SSTR, score 0–3) and the Ki-67 index were assessed. The immunohistochemical findings were compared with the 68Ga-DOTATATE PET uptake in these tumors using the SUVmax (standardized uptake value). Both values were compared with the Ki-67 proliferation index.

Results

The SUVmax in NET without SSTR expression was significantly lower compared to those with SSTR expression (p <0.05), even though 3 out of 5 NETs with a score of 0 showed a high uptake of 68Ga-DOTATATE. The SUVmax correlated significantly (r=0.40, p <0.05) with the score of immunohistochemical SSTR expression (negative, score 0, moderate, score 1 and high, scores 2 and 3). The Ki-67 index correlated inversely with the SSTR expression score (r=−0.42, p <0.05), but not significantly with the SUVmax (r=−0.33, p=0.11).

Conclusion

68Ga-DOTATATE uptake was moderately correlated with the results of immunohistochemical SSTR analyses. However, SSTR negative NET may show high uptake of 68Ga-DOTATATE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Asnacios A, Courbon F, Rochaix P et al (2008) Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 26:963–970

    Article  PubMed  Google Scholar 

  2. Beuthien-Baumann B, Strumpf A, Zessin J et al (2007) Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 34:1604–1609

    Article  CAS  PubMed  Google Scholar 

  3. Breeman WA, de Jong M, de Blois E et al (2005) Radiolabelling DOTA-peptides with 68 Ga. Eur J Nucl Med Mol Imaging 32:478–485

    Article  CAS  PubMed  Google Scholar 

  4. Buchmann I, Henze M, Engelbrecht S et al (2007) Comparison of 68-Ga-DOTATOC PET and 111-In-DTPAOC (octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617–1626

    Article  CAS  PubMed  Google Scholar 

  5. De Jong M, Kwekkeboom D, Valkema R, Krenning EP (2003) Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 30:463–469

    Google Scholar 

  6. Decristoforo C, Mather SJ, Cholewinski W et al (2000) 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 27:1318–1325

    Article  CAS  PubMed  Google Scholar 

  7. Gabriel M, Decristoforo C, Kendler D et al (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508–518

    Article  CAS  PubMed  Google Scholar 

  8. Garin E, Le Jeune F, Devillers A et al (2009) Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 50:858–864

    Article  CAS  PubMed  Google Scholar 

  9. Hartmann H, Zophel K, Freudenberg R et al (2009) Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin 48:201–207

    CAS  PubMed  Google Scholar 

  10. Haug A, Auernhammer CJ, Wangler B et al (2009) Intraindividual comparison of (68)Ga-DOTATATE and (18)F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 36:765–770

    Article  CAS  PubMed  Google Scholar 

  11. Kauhanen S, Seppanen M, Minn H et al (2007) Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab 92:1237–1244

    Article  CAS  PubMed  Google Scholar 

  12. Kayani I, Bomanji JB, Groves A et al (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 112:2447–2455

    Article  PubMed  Google Scholar 

  13. Miederer M, Seidl S, Buck A et al (2009) Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36:48–52

    Article  CAS  PubMed  Google Scholar 

  14. Montravers F, Grahek D, Kerrou K et al (2006) Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 47:1455–1462

    CAS  PubMed  Google Scholar 

  15. Papotti M, Bongiovanni M, Volante M et al (2002) Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461–475

    Article  CAS  PubMed  Google Scholar 

  16. Prasad V, Ambrosini V, Hommann M et al (2009) Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37:67–77

    Article  Google Scholar 

  17. Ruf J, Heuck F, Schiefer J et al (2010) Impact of multiphase Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 91:101–109

    Article  CAS  PubMed  Google Scholar 

  18. Seemann MD (2007) Detection of metastases from gastrointestinal neuroendocrine tumors: prospective comparison of 18F-TOCA PET, triple-phase CT, and PET/CT. Technol Cancer Res Treat 6:213–220

    PubMed  Google Scholar 

  19. Timmers HJ, Chen CC, Carrasquillo JA et al (2009) Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 94:4757–4767

    Article  CAS  PubMed  Google Scholar 

  20. Volante M, Brizzi MP, Faggiano A et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172–1182

    Article  CAS  PubMed  Google Scholar 

  21. Yao JC, Hassan M, Phan A et al (2008) One hundred years after „carcinoid“: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Nuklearmedizin, Klinikum der Ludwigs-Maximilians-Universität München, Campus Großhadern, Marchioninistr. 15, 81377, München, Deutschland

    A.R. Haug, R. Tiling, P. Bartenstein & M. Hacker

  2. Pathologisches Institut, Klinikum der Ludwigs-Maximilians-Universität München, Campus Großhadern, München, Deutschland

    G. Assmann

  3. Institut für Klinische Radiologie, Klinikum der Ludwigs-Maximilians-Universität München, Campus Großhadern, München, Deutschland

    C. Rist & G.P. Schmidt

Authors
  1. A.R. Haug
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Assmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Rist
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Tiling
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G.P. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Bartenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Hacker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A.R. Haug.

Additional information

Dieser Beitrag ist als eine Originalpublikation anzusehen und aus formalen Gründen im Leitthema dieser Ausgabe eingeordnet.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haug, A., Assmann, G., Rist, C. et al. Quantifizierung der Somatostatinrezeptorexpression neuroendokriner Tumoren mit der 68Ga-DOTATATE-PET/CT. Radiologe 50, 349–354 (2010). https://doi.org/10.1007/s00117-009-1972-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00117-009-1972-2

Schlüsselwörter

Keywords

Search

Navigation